Pamidronate and biochemical markers of bone turnover
- 1 January 1997
- journal article
- clinical trial
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 57 (7) , 581-586
- https://doi.org/10.3109/00365519709055280
Abstract
We have examined the response of different biochemical bone turnover markers to intravenous pamidronate administration (15 mg for 5 days) in 14 patients with Paget's disease, on days 8, 15 and 30 after pamidronate treatment. Urinary parameters of bone resorption, free pyridinolines (Pyr) and hydroxyproline (OHP), as well as serum tartrate-resistant acid phosphatase (TRAP) were measured. Two serum biochemical osteoblastic markers, alkaline phosphatase (AP) and osteocalcin (OC), were also analysed. In addition, ionic calcium (Ca2+) was measured in blood, and parathyroid hormone and calcitriol were measured in serum. All the biochemical markers of bone resorption tested decreased throughout the study. TRAP levels decreased slowly, meanwhile Pyr decreased maximally, below OHP values on day 8. However, the latter were lowest and were lower than those of Pyr on days 15 and 30. AP serum values also decreased during the study. Conversely, OC serum levels increased on days 8 and 15. decreasing to baseline levels on day 30. Ca2+ blood levels decreased while PTH plasma levels increased at all times during the period studied. Calcitriol serum levels increased on day 15. In conclusion, intravenous pamidronate administration was found to modify several biochemical parameters of bone turnover, including Pyr. Moreover, the changes in these parameters were different in intensity and “time course” during the study.Keywords
This publication has 23 references indexed in Scilit:
- Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretionJournal of Bone and Mineral Research, 1995
- Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's diseaseJournal of Bone and Mineral Research, 1995
- New markers of bone metabolism: clinical use in metabolic bone diseaseActa Endocrinologica, 1995
- The diagnostic validity of urinary free pyridinolines to identify women at risk of osteoporosisCalcified Tissue International, 1994
- Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosisJournal of Bone and Mineral Research, 1993
- Immunoassay for urinary pyridinoline: The new marker of bone resorptionJournal of Bone and Mineral Research, 1993
- Immunoassay of pyridinoline crosslink excretion in normal adults and in paget's diseaseJournal of Bone and Mineral Research, 1993
- Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosisJournal of Bone and Mineral Research, 1991
- Effect of Menopause and Hormone Replacement Therapy on the Urinary Excretion of Pyridinium Cross-LinksJournal of Clinical Endocrinology & Metabolism, 1991
- Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone diseaseBone and Mineral, 1990